Banner Alzheimer's Institute, 901 East Willetta Street, Phoenix, AZ 85006, USA.
Neuroimage. 2012 Jun;61(2):505-16. doi: 10.1016/j.neuroimage.2011.11.075. Epub 2011 Dec 7.
Over the last 20 years, there has been extraordinary progress in brain imaging research and its application to the study of Alzheimer's disease (AD). Brain imaging researchers have contributed to the scientific understanding, early detection and tracking of AD. They have set the stage for imaging techniques to play growing roles in the clinical setting, the evaluation of disease-modifying treatments, and the identification of demonstrably effective prevention therapies. They have developed ground-breaking methods, including positron emission tomography (PET) ligands to measure fibrillar amyloid-β (Aβ) deposition, new magnetic resonance imaging (MRI) pulse sequences, and powerful image analysis techniques, to help in these endeavors. Additional work is needed to develop even more powerful imaging methods, to further clarify the relationship and time course of Aβ and other disease processes in the predisposition to AD, to establish the role of brain imaging methods in the clinical setting, and to provide the scientific means and regulatory approval pathway needed to evaluate the range of promising disease-modifying and prevention therapies as quickly as possible. Twenty years from now, AD may not yet be a distant memory, but the best is yet to come.
在过去的 20 年里,脑成像研究取得了非凡的进展,并将其应用于阿尔茨海默病(AD)的研究。脑成像研究人员为 AD 的科学理解、早期检测和跟踪做出了贡献。他们为成像技术在临床环境中的应用、疾病修饰治疗的评估以及明显有效的预防治疗方法的确定奠定了基础。他们开发了开创性的方法,包括正电子发射断层扫描(PET)配体来测量纤维状淀粉样蛋白-β(Aβ)沉积、新的磁共振成像(MRI)脉冲序列和强大的图像分析技术,以帮助实现这些目标。需要开展更多的工作来开发更强大的成像方法,以进一步阐明 AD 易感性中 Aβ和其他疾病过程的关系和时间进程,确定脑成像方法在临床环境中的作用,并提供科学手段和监管批准途径,以尽快评估一系列有前途的疾病修饰和预防治疗方法。从现在起 20 年后,AD 可能还不会成为遥远的记忆,但最好的还在后头。